New NHS digital exercise and lifestyle programme to benefit patients with kidney disease, heart conditions and diabetes

People living with kidney disease, heart failure, diabetes and other closely linked health conditions are being offered a powerful new way to improve their health, without even leaving home.

A new NHS-commissioned digital programme across parts of London is giving patients free access to Kidney Beam, a specialist app designed to help people with cardiovascular, kidney and metabolic (CKM) conditions become more active, eat better, and manage their health more effectively.

For patients in Barnet, Camden, Enfield, Haringey and Islington, this could be a real game-changer.

Why This Matters

CKM conditions are rising fast across the UK, and the numbers are alarming.

Around 7.2 million people are living with chronic kidney disease, 7.6 million have cardiovascular disease, and around 6 million have diabetes. Many people are managing more than one of these conditions at the same time.

Add in obesity and high blood pressure, and the pressure on NHS services becomes even greater.

Charity Kidney Research UK has awarned the growing number of cases represents a “public health emergency” that could overwhelm the NHS by 2033.

What Is Kidney Beam?

Kidney Beam is a digital health platform offering physiotherapist-led exercise sessions, education classes, dietary guidance and personalised health coaching.

Unlike generic fitness apps, this programme is specifically designed for people living with CKM conditions, so the advice and activity plans are tailored to their medical needs.

Patients with early-stage disease can even self-register for online classes, helping them take action before their condition becomes more serious.

For those with more advanced illness, clinicians from Royal Free Hospital can refer patients for extra support, including a structured 12-week virtual programme with specialist health coaches.

Exercise Really Can Change Outcomes

Professor Sharlene Greenwood, consultant physiotherapist at King's College Hospital London and co-founder of the Beam programme, told That's Health that the benefits are "significant."

Regular movement for people with kidney, heart and metabolic disease can reduce mortality, improve overall health, and lower the need for hospital treatment and medication.

That is not just good news for patients, it also helps reduce pressure on overstretched NHS services.

Proven Results. This is not just theory.

A major clinical trial published in The Lancet Digital Health found Beam significantly improved patients’ quality of life and delivered NHS savings of around £580 per patient.

That is a strong reminder that prevention and rehabilitation are often far more effective, and affordable, than waiting for health problems to worsen.

A Smarter Future for Healthcare

This programme shows exactly where modern healthcare should be heading: prevention, early intervention, and support people can access from home.

Sometimes improving your health does not start with another prescription.

Sometimes it starts with simply getting moving.

http://www.kidneybeam.com

Long Covid Can’t Be Ignored Anymore. Now Action Must Follow

During March which is Long Covid Awareness Month, the UK COVID-19 Inquiry has delivered a long-overdue reality check: COVID-19 spreads through the air, and the early responses got it wrong.

For many, this confirmation isn’t new. Patients, clinicians and researchers have been raising the alarm for years, particularly around how COVID-19 spreads through the air. 

Now, it’s official: initial guidance failed to properly recognise airborne transmission, potentially allowing avoidable infections, and long-term illness, to take hold.

The Inquiry also acknowledges something equally important: Long Covid is real, serious, and for some, life-changing. 

If you’re unfamiliar with the condition, understanding what is Long Covid and how does it affect the body is key to recognising its impact.

Millions across the UK have lived this reality. Many have faced delayed diagnoses, inconsistent care, or worse, not being believed at all. 

The report admits that why healthcare access varies across the UK remains a major issue, with patients experiencing a postcode lottery in treatment and support.

Research gaps continue to be a concern. While studies into the long-term effects of COVID-19 on health are ongoing, funding has been scaled back at a time when answers are urgently needed.

Perhaps most concerning is the impact on younger people. There is growing awareness around supporting children living with Long Covid, as the condition continues to disrupt education, development, and daily life at a critical stage.

This isn’t a problem that’s gone away. Long Covid is not a legacy issue, it’s ongoing, and remains a public health concern affecting individuals, families, and communities across the UK.

Every infection still carries risk. And every preventable infection risks long-term consequences. That’s why understanding symptoms of Long Covid explained can help people seek help earlier and avoid worsening health outcomes.

Advocates argue that recognising airborne transmission must now lead to meaningful change. If the virus spreads through the air, then prevention strategies must reflect that reality — especially in healthcare settings where vulnerable people are most at risk.

Right now, protections remain inconsistent. Patients continue to face challenges around support available for Long Covid patients in the UK, with gaps in services and long waiting times still common.

The message from campaigners is clear: recognition is not enough.

What’s needed now is action, including stronger airborne infection controls, better access to protective equipment, and renewed focus on how health policy affects patient outcomes.

There’s also a broader issue at stake. Many people are still learning about coping with chronic illness in everyday life, often without adequate guidance or support.

The Inquiry has taken an important step by acknowledging both airborne transmission and the reality of Long Covid.

But without decisive action, the same mistakes risk continuing.

Long Covid isn’t slowing down.

And neither should the response.

https://www.longcfoundation.org/long-covid-awareness-day-and-month

British Liver Trust launches campaign to tackle late diagnosis of rare liver conditions

The British Liver Trust has launched a new campaign ahead of Rare Disease Day to tackle the late diagnosis of rare liver conditions, after new analysis of patient survey data revealed that many people experienced symptoms before diagnosis. 

Yet around a quarter of symptomatic patients had their concerns dismissed or were sent home without further investigation.

Liver disease is often associated with alcohol or lifestyle factors. But many rare liver conditions are autoimmune or genetic, affecting people of all ages, including babies, children and young adults. 

This misconception can contribute to delays in diagnosis and prevent people from seeking timely support.

Analysis of responses from more than 1,000 people living with rare liver conditions across the UK found that around one in five patients who experienced symptoms were diagnosed “very late”, when their disease had already progressed and treatment options were limited.

In response, the British Liver Trust has launched No One Left Behind, a new campaign aimed at shining a spotlight on rarer liver conditions that are too often under-recognised and misunderstood.

The campaign calls for greater awareness of early warning signs among healthcare professionals and the public, improved information and support at diagnosis, and greater investment in research.

Persistent itching, nausea, abdominal pain and jaundice were among the most commonly reported early warning signs across rarer liver conditions, including Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC). These are chronic, progressive diseases that often require lifelong specialist care. In some cases, delayed diagnosis can lead to cirrhosis, liver failure or the need for transplantation.

According to the British Liver Trust, tens of thousands of people in the UK are living with rare liver diseases, many of which can take years to diagnose due to a lack of awareness and limited research.

Emma was diagnosed with autoimmune hepatitis more than two decades ago, aged just 17, after developing severe itching and jaundice and spending weeks in hospital undergoing tests. At the time, she had never heard of the condition and did not recognise that her symptoms were signs of serious liver disease.

Emma told That's Health: “So many people don’t realise liver disease doesn’t just affect people who drink alcohol. Conditions like mine are called ‘rare’, but they affect thousands of people.”

Rare Disease Day is marked globally each year on 28 February and aims to raise awareness of rare diseases and improve access to diagnosis, treatment and care for those affected.

Pamela Healy OBE, Chief Executive of the British Liver Trust, added: “Rare liver diseases may be less common, but for the thousands of people affected across the UK, their impact is life-changing. Too often, a lack of awareness leads to delayed diagnosis and unequal access to specialist care. 

"We need greater understanding, earlier diagnosis and sustained investment in research to ensure no one living with a rare liver condition is left behind.”

The British Liver Trust is the UK’s leading liver health charity and provides information, support and advocacy for everyone affected by liver disease. This includes people living with rare liver conditions such as autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Alagille syndrome and biliary atresia.

For more information, visit www.britishlivertrust.org.uk.

Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect

Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. 

Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.

"We firmly believe in the benefits that this non-opioid treatment option can provide to people suffering from peripheral neuropathic pain and continue to work on expanding its footprint to reach more patients worldwide," Jan Adams, Chief Commercial Officer (CCO) at Grünenthal told That's Health.

"Clinect is an experienced specialist with a strong presence in Australia, and I look forward to joining forces with their team to bring our brand to Australia, a major market of the Asia-Pacific region."

"We value the opportunity to work alongside Grünenthal, a global leader in pain management, to introduce Qutenza® to the Australian market,” said Merryn Wallace, General Manager at Clinect. “This agreement reflects our shared commitment to improving patient outcomes and aligns with Clinect’s strategy of partnering with companies who bring truly differentiated therapies to our region."

Grünenthal acquired the global rights to Qutenza® in 2018 as part of its M&A-driven growth strategy. Since 2017, the company has invested more than €2.3 billion in successful M&A transactions, diversifying its portfolio, enhancing its profitability, and driving business growth. Grünenthal continues to expand the footprint of the acquired brands and to create synergies throughout Grünenthal's infrastructure, including manufacturing, supply, logistics, and commercial activities.

In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.

www.grunenthal.com

Rare Disease Day: Why Awareness Matters More Than Ever

Every year on 28 February (or 29 February in leap years), the world marks Rare Disease Day, a global campaign dedicated to raising awareness of conditions that individually affect small numbers of people, but collectively impact millions worldwide.

In the UK alone, it's estimated around 3.5 million people live with a rare disease. Globally, that figure rises to overmore than 300 million. 

Despite the numbers, many patients still face delayed diagnosis, limited treatment options and ongoing misunderstanding.

For That’s Health, this day is about shining a light on stories that are too often overlooked.

What Is a Rare Disease?

A disease is considered rare in the UK if it affects fewer than 1 in 2,000 people. However, there are more than 7,000 known rare conditions. 

Around 72% are genetic, and many begin in childhood, though others emerge later in life.

Examples include:

Huntington's disease

https://www.hda.org.uk/information-and-support/huntingtons-disease/what-is-huntingtons-disease

Cystic fibrosis

https://www.cysticfibrosis.org.uk

Ehlers-Danlos syndrome

https://www.ehlers-danlos.com/what-is-eds

Duchenne muscular dystrophy

https://www.duchenneuk.org/what-is-duchenne

Some are life-limiting. Others are chronic and complex, affecting multiple body systems and requiring specialist care.

The Challenge of Diagnosis

One of the biggest hurdles facing people with rare diseases is simply getting a diagnosis.

It can take years, sometimes decades, for patients to receive clarity. Symptoms may be misattributed, dismissed, or misunderstood. Families often describe a long and exhausting search for answers, moving from specialist to specialist.

Earlier diagnosis matters. It can:

Improve treatment outcomes

Allow families to plan and access support

Connect patients with specialist communities

Reduce mental health strain caused by uncertainty

Living With a Rare Condition

Rare diseases do not just affect physical health. They impact education, employment, finances and relationships.

People may feel isolated, especially if there are very few others locally with the same condition. Support groups, online communities and charities play a vital role in providing connection and practical advice.

In the UK, organisations such as Genetic Alliance UK and Rare Disease UK campaign for improved services, research funding and better policy support.

https://geneticalliance.org.uk

https://rd-research.org.uk

Why Awareness Still Matters

Awareness days are sometimes criticised as symbolic gestures. But for rare disease patients, visibility can lead to real change.

Awareness can:

Encourage earlier referrals and recognition by healthcare professionals

Support funding for research and innovative therapies

Influence government health strategies

Reduce stigma and misunderstanding

The UK has developed rare disease frameworks to improve coordination of care, but continued momentum is essential.

Research and Hope

Scientific advances, particularly in genetics and personalised medicine, are transforming the landscape of rare disease treatment. Gene therapies, targeted biologics and improved diagnostic tools are offering new hope.

However, research into rare diseases often receives less funding due to smaller patient populations. Advocacy remains crucial to ensure progress continues.

How You Can Support Rare Disease Day

You do not need to be directly affected to make a difference. You can:

Share information on social media

Support rare disease charities

Learn about conditions affecting people in your community

Encourage compassionate conversations

Even a small action can reduce isolation for someone living with a rare diagnosis.

Rare diseases may be individually uncommon, but collectively they represent a significant public health issue. Behind every statistic is a person navigating uncertainty, resilience and strength.

Rare Disease Day reminds us that awareness is not just about facts and figures, it is about empathy, research, and ensuring that no one feels invisible.

For more health awareness features and UK-focused wellbeing content, keep following That’s Health.

Know GvHD marks GvHD Day on February 17, 2026, with “Together through GvHD” campaign

Image courtesy gvhdhub.com

Know GvHD will mark GvHD Day on Tuesday February 17, 2026, uniting patients, caregivers, ambassadors, societies, and the wider community to raise awareness of graft-versus-host disease (GvHD) and the long-term impact it can have on those affected.

GvHD Day aims to shine a light on the ongoing physical and psychological effects of GvHD and its treatment, as well as the continuing need for education, support, and connection. 

Many people remain unaware of the long-term biological, physical, and emotional challenges associated with GvHD, the supportive care options available, and where patients, caregivers, and families can find trusted information and practical guidance. GvHD Day 2026 seeks to address these gaps by making easily-accessible, patient-focused resources available to the entire GvHD community.

Together through GvHD

This year’s campaign – Together through GvHD – is rooted in connection, understanding, and hope. It is a reminder to every patient and caregiver affected by GvHD that they are not alone and that support, information, and community are within reach.

Connect. Share. Feel supported.

As part of the campaign, Know GvHD is bringing together a range of supportive resources and peer networks for people affected by GvHD. This includes a new Support Groups section on the website, featuring links to trusted organizations and communities where patients and caregivers can find help, connection, and shared experiences.

The campaign also includes a dedicated WhatsApp support group, hosted by Know GvHD patient ambassadors. This supportive and welcoming space allows people living with GvHD to connect with others who understand, share experiences, ask questions, and find reassurance from peers navigating similar challenges.

Be part of GvHD Day

To help drive awareness and visibility on February 17, Know GvHD is inviting supporters to take part in a simple but meaningful activity:

Download a Know GvHD poster from the website or order printed copies

Take a photo with the poster

Share the photo on social media and tag Know GvHD

This collective action reflects the spirit of Together through GvHD, highlighting the importance of connection, visibility, and community for everyone affected by GvHD.

Helping patients at every step of their journey

Know GvHD is also introducing Know GvHD business cards, designed to raise awareness of the website as a trusted hub where patients and caregivers can:

Access clear, reliable education

Connect with others who understand GvHD

Find ongoing support and reassurance

Posters and business cards will be distributed across blood and marrow transplantation centers, hospitals, and relevant societies, helping ensure that patients encounter Know GvHD at key moments in their journey. Information on how to order business cards is available on the website here: https://know-gvhd.com/gvhd-day/

Help spread the word

Please share and disseminate Know GvHD resources, including:

Patient stories

Patient interviews

WhatsApp invite link

Downloadable poster and business cards

Know GvHD website link

When sharing on social media, please use these official hashtags:

#GvHDDay #GVHDAlliance #GvHDConnect4Hope

Together, the community can raise awareness, strengthen connections, and help build a more supportive future for everyone affected by GvHD.

Together through GvHD, because no one should face GvHD alone.

For more information on GvHD Day, please visit:

https://know-gvhd.com/gvhd-day

https://scientificeducationsupport.com

https://gvhdhub.com

“My handstand challenge for best mate whose life was turned upside down.”

When illness turned Ellis Healy’s life upside down, his best mate Harry turned upside down too - by committing to doing a handstand every day in 2026 to raise money for charity.

Harry Clesham, who lives in southwest London, has already raised over £2,000 for The Brain Tumour Charity via social media and his fundraising page – and his technique has improved to the stage where he can walk a few steps on his hands too.

He posts daily videos of his activities on Instagram, and carries out his feats in locations as varied as pubs, pavements, gyms, holiday hotspots and hotel rooms.

Harry and Ellis first met when they were students at university in Leicester in 2011. They lived in the same halls of residence, hung out together during Freshers’ Week and both joined the rugby team.

Ellis, 33, who had intended to become a butcher like his dad, then worked in London for a year, as did Harry. They sat their finals in Leicester and then both moved back to London to work at tech companies. Harry was also a groomsman and the Master of Ceremonies when Ellis married his wife Hannah in 2024.

But Ellis has had health struggles since he was diagnosed with Crohn’s disease when he was 11. Treatment included immunosuppressant medication which stopped working when he was 27.

While waiting to have scheduled keyhole surgery, he was rushed to hospital with a blockage in his intestine. This was found to be tumour, and to his shock, he was diagnosed with non-Hodgkin lymphoma. Fortunately, it had been caught early and he was treated with six rounds of R-CHOP chemotherapy – a combination of four drugs and a steroid.

That's where his good fortune ended. A PET scan to check he had the all-clear found no uptake of the contrast dye on the right side of his brain. A follow up scan identified a brain tumour.

Ellis told That's Health: “I was due to have keyhole surgery to treat my Crohn’s but ended up having four lots of surgery and two bouts of sepsis which triggered a cardiac arrest.

“I was discharged with a wearable defibrillator vest and was one of the first patients in the UK to use one. I had to wear it for 24 hours a day, including at work and at the gym which was awkward.”

Once his infection had gone, brain tumour treatment was due to start. But first he needed to have a permanent defibrillator implanted. Then, last March, Ellis had three seizures back-to-back.

Ellis continued: “I had my first seizure while I was asleep. It woke my wife who called an ambulance which arrived within 10 minutes. They gave me a sedative which stopped the seizure, but I had another one a short while later and another one in the ambulance.”

Six months after the seizures and the ICD Implant, Ellis had an awake craniotomy to remove a grade 2 to 3 astrocytoma, from which he’s now recuperating.

Throughout everything, Harry has supported Ellis as best he can – taking the mickey out of his fashion sense when he was wearing the defibrillator vest, and when he was well enough, going camping on the Dorset coast. That’s when the idea to raise awareness and funds came about.

Harry said: “Ellis has been an exceptional friend and we’ve been close pals ever since we met. His strength, humour and resilience throughout have been nothing short of inspiring - I truly haven’t met anyone like him. He’s one of a kind.

“The challenge was born after Ellis and I spent two days walking together along the Jurassic Coast. We talked about what he was going through, how he was feeling and what I could do to support him in a meaningful way. During those conversations, Ellis said that if I were to raise money for a cause, he would want it to be for The Brain Tumour Charity.”

Ellis added: “I mentioned The Brain Tumour Charity because their website and leaflets provide all the information you need to know - not just about living with the illness but also how to prepare for what’s next and how to overcome some of the challenges you’re going to face.

“It's just a really good single point of reference so I’ve used it a lot and it’s been very helpful for my family to understand it as well, in their own time.”

You can support Harry’s fundraising efforts here: https://www.justgiving.com/page/officialhandstandharry – and watch his daily handstand videos on Instagram @officialhandstandharry.

Harry said: “The rule is simple: no matter what the day brings, there is always time to show up for this cause. This challenge is about more than handstands. It is about standing alongside a friend as he recovers from brain tumour surgery, raising awareness of the impact brain tumours have on individuals and their families, and supporting the research, care and services provided by The Brain Tumour Charity. 

"I will keep going, one day, one handstand and one donation at a time, for Ellis and for everyone affected by brain tumours.”

Urgent action needed as new research reveals gaps in fatty liver disease diagnosis and care

New research released to coincide with Global Fatty Liver Day has found that fatty liver disease is being consistently overlooked, leading to late diagnosis. 

This discovery comes from analysis of a survey of patients with fatty liver disease, which found that more than half reported receiving no support following their diagnosis, and a third were diagnosed at a late stage.

Fatty liver disease, also known as MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), is estimated to affect up to 1 in 5 people in the UK. The main risk factors are being overweight, an unhealthy diet or living with type 2 diabetes.

A survey conducted by the British Liver Trust found that among 687 people living with MASLD:

• 68% were overweight or obese

• 35% had type 2 diabetes

More than half (55%) said they had received no support with weight management, eating a healthy diet or physical activity, which is the cornerstone for successful treatment of this disease. In the early stages, reducing weight and improving diet can either halt disease progression or even reverse liver damage. 

Additionally, over a third of respondents said their diagnosis came at a late stage, when it was too late for effective treatment.

With an estimated two thirds of the UK population classed as overweight or obese, the charity is calling for better awareness among both the general population and healthcare professionals. The British Liver Trust is urging widespread, systematic case finding, including routine testing and liver scanning for people at risk—to enable earlier diagnosis and better outcomes. 

The charity also highlights the need for new treatments to be introduced alongside comprehensive education for healthcare professionals, to ensure patients receive appropriate support at the right time.

MASLD is affecting an increasing number of people across the UK. Mortality rates in England alone rose by 44% between 2019 and 2023, with the highest rates seen in the North of England.

Pamela Healy OBE, CEO at the British Liver Trust, told That's Health: “For too long, widespread misunderstandings around liver health have meant that large numbers of people are unaware of the risks to their liver from being overweight, or from eating too much unhealthy or ultra-processed food. People are frequently told how these lifestyle factors increase their risk of heart disease and type 2 diabetes, but the risk of fatty liver disease is rarely discussed.

“We want to see MASLD to be given the same attention as other major conditions, and we need effective changes to ensure that everyone at risk receives the right treatment at the right time.”

Sara’s father was told he had a fatty liver in 2014 and only received one scan in 2016. In 2024, he was diagnosed with MASLD and died just four months later in July 2024, aged 62. Sara and her family are still trying to come to terms with his tragic, and ultimately preventable, death: “If we’d got that MASLD diagnosis a little bit sooner, if he’d just had a few more weeks, and if he had been put under surveillance a few years earlier, they would have seen his liver was getting worse and it wouldn’t have got to this point.”

“MASLD is a growing public health concern across the UK,” said Professor Philip Newsome, a leading liver expert from King’s College Hospital London and medical advisor to the British Liver Trust. “We are seeing promising advances in research with several new treatments showing encouraging results. However, there is an urgent need to translate these developments into clinical practice, ensuring early detection and better treatments are embedded within the NHS to deliver real benefits for patients.”

https://britishlivertrust.org.uk

EU Ban Poses New Risk To Walkers And Outdoor Workers

Tick-borne disease charity BADA-UK (Borreliosis and Associated Diseases Awareness-UK) and Patron Ray Mears are warning people to be especially vigilant in rural areas over the coming months.

The charity is using its annual awareness campaign Tick Bite Prevention Week (26 March - 1 April) to highlight the increased risk of contracting tick-borne diseases following the EU ban of Asulam, a herbicide used by hill farmers to control the invasive spread of bracken. This plant provides a perfect habitat for ticks.

Ticks are second only to mosquitoes for carrying disease to humans worldwide and are responsible for transmitting Lyme disease (Borreliosis), which can lead to serious complications including damage to the nervous system, joints, heart and other tissues.

Latest figures from the Health Protection Agency show that 953 laboratory-confirmed cases of Lyme disease (Borreliosis), which is contracted from an infected tick bite, were reported in England and Wales in 2010.

Two-thirds of these were identified in the South of England but have also been reported from most counties. Infections occur most frequently in Exmoor, the New Forest, the South Downs, parts of Wiltshire and Berkshire, Surrey and West Sussex, Thetford Forest, the Lake District and the North York Moors. However, the Health Protection Agency states that any area where Ixodid ticks are present should be regarded as a potential risk area.

Authorities acknowledge an under reporting of cases and estimate that around 3,000 people contract Lyme disease each year in the UK, whilst latest research published in January 2012 by the School of Biological Sciences, at the University of Bristol, suggests that the prevalence of Lyme disease bacteria in the UK tick population is considerably higher than most recent estimates indicated.

TV Bushcraft and Survival expert and BADA-UK Patron Ray Mears warns: "The control of bracken is vital to the survival of numerous species of flora and fauna as well as reducing tick populations.

The spread of bracken as a result of the Asulam ban will lead to increased tick numbers making it all the more important that the public takes precautions against tick bites when out and about in rural areas."

BADA-UK advises that the best defence against tick-borne infection is to avoid being bitten in the first place by taking a few simple precautions when out walking. These include wearing protective clothing and using an effective insect repellent.

Wendy Fox, Chair of BADA-UK, who has been left disabled by Lyme disease, says: "We understand perhaps better than most the devastating effects that tick-borne diseases can have if not diagnosed and treated promptly.

Therefore, we strive to help prevent others from falling victim to them. People who frequent bracken-rich areas can be recreationally and occupationally exposed to tick-borne disease, particularly Lyme disease. Increased interest in outdoor pursuits, combined with an increasing tick population is resulting in a year-on-year rise in cases of tick-borne disease."

In 2012, BADA-UK and Tick Bite Prevention Week are once again being supported by Mosi-guard® Natural.

Asbestos Claims Litigation Yielding Larger Jury Awards in US Courts

Danziger & De Llano, a leading Houston law firm specialising in asbestos-related liability cases, reports 2011 saw a continuation of a decade-long trend toward fewer cases nationwide but higher individual jury awards.

And Houston is broadly in line with these national trends, says Danziger & De Llano partner Paul Danziger.

"As more companies bring their work site operations into full compliance with asbestos safety laws there has been a dividend in lives saved," notes Danziger. "Sadly, though, there are also fewer victims of past asbestos abuse who survive each passing year." Danziger adds that courts have been more successful in reducing the backlog of asbestos cases in recent years.

The figures on asbestos related liability cases compare the years 2001 and 2011.

According to Danziger, whose law practice handles cases from across the entire nation, while the total number of cases in the nation's courts have fallen by roughly twenty percent in that period--today's jury awards are up to two times greater than those of 2001.

"More public awareness of lax past safety practices in industry, along with legislation which better safeguards worker rights, have helped juries arrive at damage awards which are much more appropriate," he notes. "Part of the dynamic helping push jury awards up is the greater availability of public information on asbestos dangers."

Danziger's own law firm sponsors www.Mesocare.org, a public service website with links to resources available to families affected by mesothelioma.

Treat Coronary Heart Disease in Safety with New Thermobalancing Therapy States Fine Treatment

Fine Treatment introduces a new natural device to help prevent or control coronary heart disease and so reduce the risk of a first or repeat heart attack

New Thermobalancing Therapy for prevention and treatment of coronary heart disease(CHD) is now available at Fine Treatment worldwide. Dr. Allen’s Device for Heart Treatment is essential care of the heart as it works 24 hours a day (day-by-day) improving the condition of the heart muscle. See the video on this page where the interviewer form Oxford Innovation Centre asks questions and the interviewee, one of the Fine Treatment’s patients, answers to them.

As follows from the video, 89 year old lady has recovered from heart failure over 2-years ago and enjoys her life pain free because she wears Dr. Allen’s Device for Heart Treatment.

According to the Centres for Disease Control and Prevention (or CDC) each year heart disease kills more Americans than cancer. In recent years, cardiovascular risk in women has been increasing and has killed more women than breast cancer. So the most dangerous disease which causes one in three deaths in the USA can have a safe cure now.

Fine Treatment introduces a new natural device for the heart treatment that everyone will be able to use at home. The major ingredient the natural thermo-element is incorporated in the vest which keeps this thermo-element near to the heart increasing the blood flow inside the heart muscle. Learn more about how easy is to apply the thermo-element to the heart are by watching this video: http://www.youtube.com/watch?v=UeKMF8UMPMk

“A natural coronary heart disease treatment that reaches your heart is the best way to improve condition of the heart muscle,” says Dr Allen. “Keep the heart muscle in a healthy condition and enjoy your life pain free.”

Dr Allen’s Device for Heart Treatment tackles the cause of the heart problems: by creating a favourable situation for the fine blood capillaries to stabilise the body temperature within the tissue of the heart. This improves the blood flow in the heart muscles on the capillary level which reduces the micro-swelling in the walls of coronary arteries dropping the internal pressure and, thus, stopping pain and discomfort. In addition, the heart muscle gets sufficient nutrients for the processes of recovery. Read more at the Fine Treatment website: www.finetreatment.co.uk/natural-alternative/heart-treatment.html.

FACTFILE:
Dr. Simon Allen is a highly experienced medical professional. His specialty is in the cardio-vascular field and he treated patients with coronary heart disease, joints, kidneys and prostate conditions. Fine Treatment produces and distributes devices for the prostate conditionssuch as chronic prostatitis and BPH, coronary heart disease, to dissolve kidney stones and to relieve back pain in the upper and lower spine.